Asian Journal of Cardiology Research

Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality, affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13-30% of hypertensive patients, poses a challenge in treatment escalation, contributing to clinical inertia. Sacubitril/valsartan, a dual-action compound comprising valsartan (an angiotensin receptor blocker) and sacubitril (a neprilysin inhibitor), has garnered approval in China and Japan for Hypertension and FDA approval for heart failure. This article aims to review the possibility of sacubitril/ valsartan as an alternative therapy for the treatment of hypertension. Clinical evidence indicates sacubitril/valsartan's efficacy in reducing blood pressure. Notably, it also demonstrates significant blood pressure reductions in patients with heart failure, emphasizing its dual benefits. The compound's superior efficacy in improving hypertension and left ventricular hypertrophy is a focus of ongoing investigations. This review highlights the role of sacubitril/valsartan as a promising therapeutic option for the management of hypertension.